Furthermore, increasing number of
drug approvals are expected to propel growth of the global Pertuzumab
Market. For instance, in December 2017, the U.S. Food and Drug
Administration (U.S FDA) granted approval to PERJETA, a pertuzumab produced by
Genentech, Inc. for its use in combination with trastuzumab and chemotherapy as
adjuvant treatment of patients with HER2-positive early breast cancer at high
risk of recurrence.
Pertuzumab is a recombinant
monoclonal antibody that acts as an antineoplastic agent, which targets the
human epidermal growth factor receptor 2 protein known as HER2. The drug blocks
signaling pathways that leads to cell growth arrest and apoptosis (cell
destruction), thereby inhibiting the proliferation of human tumor cells.
Pertuzumab was found to aid in the treatment of HER2 associated breast cancer
and was developed by Genentech, Inc., a subsidiary of F. Hoffmann-La Roche AG.
It was first approved by U.S. Food and Drug Administration in 2012.
Pertuzumab Market– Drivers
There are increasing number of
clinical trials for use of pertuzumab in combination with other drugs for the
treatment of breast cancer . For instance, Helsinki University Central Hospital
is undergoing phase III clinical study for adjuvant trastuzumab, pertuzumab,
and docetaxel in the treatment of early HER2 positive breast cancer. The study
was started in December 2015 and is estimated to complete by June 2023.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2256
Moreover, development of novel
anticancer drug delivery technologies is expected to boost growth of the
market. For instance, in July 2018, Gentech, Inc., in partnership with Halozyme
Therapeutics, Inc., used proprietary ENHANZE drug-delivery technology of
Halozyme Therapeutics, Inc., for subcutaneous administration of fixed-dose
combination of pertuzumab (PERJETA) and trastuzumab (Herceptin). This study is
under clinical phase III trial. ENHANZE technology aids in reducing the need
for multiple injections and reduces time required for drug administration.
Pertuzumab Market– Restraint
Increasing cost of anticancer
drugs is expected to be a major factor hampering growth of the market. For
instance, in June 2017, The Scottish Medicines Consortium (SMC) denied access
to pertuzumab in England, which was available via the Cancer Drugs Fund (CDF)
in Europe. The drug was rejected by SMC as the treatment of HER2 positive
breast cancer was not cost effective when pertuzumab was used in combination with
trastuzumab and docetaxel.
Moreover, according to a study
published in the journal Oncology, September 2015, although the use of
pertuzumab with docetaxel and trastuzumab as first-line therapy for HER2
positive breast cancer has been shown to yield a substantial survival benefit,
the therapy is not cost effective in the U.S. Also, according to the same
source, the cost of treating HER2 positive breast cancer with pertuzumab and
other drugs is US$ 509,845 and that with only docetaxel and trastuzumab is US$
135,092.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/pertuzumab-market-2256
Pertuzumab Market– Regional
Analysis
On the basis of region, the
global pertuzumab market is segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold
dominant position in the global pertuzumab market due to increasing prevalence
of breast cancer among women in the U.S. For instance, according to American
Cancer Society 2017, around 52,710 new cases of invasive breast cancer were
diagnosed in 2017 among women in the U.S. and around 40,610 women were expected
to die due to breast cancer in the U.S. in same year.
Furthermore, Asia Pacific is
expected to witness significant growth in the global pertuzumab market, owing to
increasing awareness of breast cancer and its management. For instance, in
November 2016, India launched National Cancer Screening Program to increase
awareness and early detection of breast cancer. This framework aims to offer
mechanism for effective screening and management of common cancers.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2256
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment